Iovance Biotherapeutics
Commercializes TIL cell therapies for melanoma and other solid-tumor settings.
$8.03
After-hours close+0.00 (+0.06%)
At close$8.03(−2.85%)
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Nov 2026 | −$0.12 | — | — |
| Aug 2026 | −$0.13 | −$0.11 | +17.6% |
| May 2026 | −$0.19 | −$0.19 | 0.0% |
| Feb 2026 | −$0.22 | −$0.18 | +18.2% |
| Nov 2025 | −$0.29 | −$0.25 | +13.8% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Feb 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Feb 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Feb 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Feb 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Feb 2020 | |||
| Nov 2019 | |||
| Aug 2019 | |||
| May 2019 | |||
| Feb 2019 | |||
| Nov 2018 | |||
| Aug 2018 | |||
| May 2018 | |||
| Mar 2018 | |||
| Oct 2017 | |||
| Aug 2017 | |||
| May 2017 | |||
| Mar 2017 | |||
| Nov 2016 | |||
| Aug 2016 | |||
| May 2016 | |||
| Mar 2016 | |||
| Nov 2015 | |||
| Aug 2015 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise |
|---|---|---|---|---|---|---|
| Nov 5, 2026 | −$0.12 | — | — | $110.1M | — | — |
| Aug 6, 2026 | −$0.13 | −$0.11 | +17.6% | $87.8M | $99.3M | +13.1% |
| May 7, 2026 | −$0.19 | −$0.19 | 0.0% | $77.8M | $71.4M | −8.2% |
| Feb 24, 2026 | −$0.22 | −$0.18 | +18.2% | $80.7M | $86.7M | +7.4% |
| Nov 6, 2025 | −$0.29 | −$0.25 | +13.8% | $82.2M | $67.5M | −17.9% |
The latest year is open to everyone — the 41 quarters behind it read with an account. Sign in | ||||||
| Aug 7, 2025 | ||||||
| May 8, 2025 | ||||||
| Feb 27, 2025 | ||||||
| Nov 7, 2024 | ||||||
| Aug 8, 2024 | ||||||
| May 9, 2024 | ||||||
| Feb 28, 2024 | ||||||
| Nov 7, 2023 | ||||||
| Aug 8, 2023 | ||||||
| May 9, 2023 | ||||||
| Feb 28, 2023 | ||||||
| Nov 3, 2022 | ||||||
| Aug 4, 2022 | ||||||
| May 5, 2022 | ||||||
| Feb 24, 2022 | ||||||
| Nov 4, 2021 | ||||||
| Aug 5, 2021 | ||||||
| May 6, 2021 | ||||||
| Feb 25, 2021 | ||||||
| Nov 5, 2020 | ||||||
| Aug 6, 2020 | ||||||
| May 5, 2020 | ||||||
| Feb 25, 2020 | ||||||
| Nov 4, 2019 | ||||||
| Aug 1, 2019 | ||||||
| May 7, 2019 | ||||||
| Feb 27, 2019 | ||||||
| Nov 6, 2018 | ||||||
| Aug 6, 2018 | ||||||
| May 10, 2018 | ||||||
| Mar 12, 2018 | ||||||
| Oct 31, 2017 | ||||||
| Aug 1, 2017 | ||||||
| May 1, 2017 | ||||||
| Mar 7, 2017 | ||||||
| Nov 4, 2016 | ||||||
| Aug 8, 2016 | ||||||
| May 9, 2016 | ||||||
| Mar 10, 2016 | ||||||
| Nov 5, 2015 | ||||||
| Aug 10, 2015 | ||||||